#### Adverse events (%)

| Outcome | Indacaterol+tiotropium | Placebo+tiotropium |
| :--------------------------- | :--------------------- | :----------------- |
| Cough | 9,1 | 4,4 |
| Muscle spasm | 0,3 | 1,1 |
| Plasma potassium <3,5 mmol/L | 1,6 | 1,4 |
| Systolic BP-high | 0,7 | 0,4 |
| QTc interval (absolute value) | 1,8 | 2,6

*post-salbutamol for FEV₁ % and FEV₁/FVC and pre/post salbutamol for reversibility

9) 경구스테로이드의 장기간 단독 사용은 권장하지 않는다(근거수준: 높음, 권고강도: 강함).

근거표 9; Oral corticosteroids

| 연구수 | 연구설계 | 비뚤림 위험 | 비일관성 | 비직접성 | 비정밀 | 출판 비뚤림 | 근거수준 |
| :----- | :------- | :---------- | :------- | :------- | :----- | :---------- | :------- |
| 24 | 무작위대조군 연구 | 없음 | 없음 | 없음 | 없음 | 없음 | 높음 |

P I C O 및 근거표

Author, year publication: Walters JAE, Cochrane Database of Systemic Review 2009
Title: Oral corticosteroids for stable chronic obstructive pulmonary disease
Search methods: A search of the Cochrane Airways Group Specialised Register of COPD trials was carried out using the terms: glucocorticoid* or hydroxycorticosteroid* or anti-inflammator* or steroid* or corticosteroid* or prednisone or prednisolone or methylprednisolone or dexamethasone or cortisone or hydrocortisone* or medrol or solumedrol or solu-medrol
A additonal search of MEDLINE was carried out using the terms: (COPD OR emphysema OR COAD OR chronic obstructive pulmonary disease OR chronic obstructive airways disease OR chronic bronchitis) AND ("adrenal cortex hormone*" OR steroid* OR glucocorticoid* OR corticosteroid* OR betamethasone OR cortisone OR dexamethasone OR hydrocortisone OR prednisolone OR prednisone OR methylprednisolone OR methylprednisone OR triamcinolone OR hydroxycorticosteroid* OR anti-inflammator* OR "anti inflammator*").
N: 24 RCT studies
Aim: To assess the effects of oral corticosteroids on the health status of patients with stable COPD
Type of studies: Randomised, placebo controlled prospective studies, single or double blind, parallel group or crossover
Type of participants: In adults with stable COPD, post-bronchodilator FEV₁<80% predicted and FEV₁/FVC<0,7 and a history of smoking
Exclusion: Known asthmatics
Type of intervention: Oral steroid vs placebo
Corticosteroid administered orally on a daily or alternate-day regimen for a minimum duration of one week
Type of outcome measures: 1st outcome; changes in FEV₁, and Health related QOL
2nd outcome
Proportion of patients who are responders to therapy
Acute exacerbation of COPD
Symptom severity
Functional capacity
Adverse effects of medications
Outcome analysis was stratified into short-term use (steroid for less than 6 weeks) and long-term use (steroid for 6 weeks or more), low dose or high dose oral steroid use, concomitant inhaled corticosteroid use and severity of disease
Results: No evidence to support the long-term use of oral steroids at doses less than 10~15 mg prednisolone though some evidence that high (≥30 mg prednisolone) improve lung function over a short period. Potentially harmful adverse effects e.g, diabetes, hypertension, osteoporosis would prevent recommending long-term use at these high doses in most patients.

<PAGE>124